Icosavax Company

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.
Industry: End-to-end Drug Development
Headquarters: Seattle, Washington, United States
Founded Date: 2017-01-01
Employees Number: 11-50
Funding Status: IPO
Investors Number: 15
Total Funding: 161000000
Estimated Revenue: $10M to $50M
Last Funding Date: 2021-04-07
Last Funding Type: Series B

Visit Website
Register and Claim Ownership